- SWOG's ASCO 2023 preview highlights Goldkorn Lab liquid biopsy research in two abstracts
May 30, 2023SWOG Presents 30 Abstracts at ASCO 2023 | SWOG "Here are highlights from some of the other SWOG work to be presented at ASCO 2023... An analysis of the prognostic value of circulating tumor cell (CTC) counts in patients with metastatic hormone-sensitive prostate cancer (mHSPC) on the SWOG S1216 trial reports that CTC count at… - Liquid Biopsies Featured in National Geographic
February 17, 2023The February issue of National Geographic magazine featured an article providing readers with a broad overview of what liquid biopsies are and what they have the potential to be. Amir was one of three leading scientists in the field interviewed for the article. View it on the website here, or see it linked below. How-liquid-biopsies-have-made-it-easier-to-treat-cancerDownload - Goldkorn Lab presents research into cell-free DNA methylation at ASCO 2022
June 30, 2022The ASCO 2022 annual meeting was held last month, and on June 3rd, the Goldkorn Lab presented an oral abstract showcasing research done in cooperation with SWOG. Using the S1314 neo-adjuvant bladder cancer cohort, researchers from the Goldkorn Lab -- led by Yi-Tsung Lu -- showed that cell-free DNA methylation patterns are a biomarker to… - Amir visits the Uromigos!
June 3, 2022Amir joins Dr. Tom Powles and Dr. Brian Rini on the Kidney Cancer Association's Uromigos podcast to discuss the results of the S1314 clinical trial, specifically how cell-free DNA methylation in bladder cancer can predict if patients will respond to chemotherapy. Listen below! - USC Norris Cancer: New Study Demonstrates Feasibility of Non-invasive Profiling of Advanced Prostate Cancer by Combining Liquid Biopsies with Radiomic Analysis of CT Scans
May 9, 2022By Hinde Kast (Originally posted at USC Norris Cancer) Cancer can evolve and adapt during therapy, leading to resistance and progression. New non-invasive technologies can track these changes in real-time, but to date, these approaches have been developed in isolation, which only allows physicians to obtain a partial idea of what is happening with a… - Liquid Biopsy Core Research featured in May/June 2021 NCCC Community for a Cure Newsletter
June 30, 2021"Drs. Amir Goldkorn, Timothy Triche, and Vinay Duddalwar awarded a new multi-investigator R01 grant from the National Cancer Institute for translational biomarker studies in advanced prostate cancer This study will be performed using liquid biopsy samples and CT scans prospectively collected in a 5-year NCI SWOG multi-center clinical trial for men with metastatic prostate cancer.… - Amir discusses SWOG S1216 next steps with CancerNetwork
July 2, 2020From CancerNetwork: "Men with metastatic castrate resistant prostate cancer (mCRPC) with undetectable circulating tumor counts (CTCs) were 6.1-fold more likely to have complete response to hormonal therapy, according to findings presented at the 2020 ASCO Virtual Scientific Program. Results from SWOG S1216, a phase III randomized trial, demonstrated that CTC count at treatment initiation was… 
Amir reviews findings from SWOG S1216 on JNCCN 360
June 9, 2020 "Amir Goldkorn, MD, of USC Norris Comprehensive Cancer Center, discusses findings from SWOG S1216, which showed that using circulating tumor cell (CTC) count at the start of treatment for metastatic castration-sensitive prostate cancer was prognostic of 7-month PSA response and progression-free survival at 2 years. He also discusses the possible challenges of integrating CTC…
Amir presents S1216 results at the 2020 ASCO Annual Meeting
May 31, 2020Watch it here: New biomarker may guide initial treatment of metastatic prostate cancer - Keck Medicine of USC (broadcastmed.net) "Prostate cancer is the most common malignancy and second most common cause of cancer death in men in the U.S., yet there are no available biomarkers to guide treatment decisions. Amir Goldkorn,…